Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F20%3A00531962" target="_blank" >RIV/68378050:_____/20:00531962 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/20:10416105 RIV/00023736:_____/20:00013044 RIV/00064165:_____/20:10416105
Result on the web
<a href="https://febs.onlinelibrary.wiley.com/doi/full/10.1002/1878-0261.12768" target="_blank" >https://febs.onlinelibrary.wiley.com/doi/full/10.1002/1878-0261.12768</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/1878-0261.12768" target="_blank" >10.1002/1878-0261.12768</a>
Alternative languages
Result language
angličtina
Original language name
Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes
Original language description
Myelodysplastic syndromes (MDS) are preleukemic disorders characterized by clonal growth of mutant hematopoietic stem and progenitor cells. MDS are associated with proinflammatory signaling, dysregulated immune response, and cell death in the bone marrow (BM). Aging, autoinflammation and autoimmunity are crucial features of disease progression, concordant with promoting growth of malignant clones and accumulation of mutations.Suprabasin(SBSN), a recently proposed proto-oncogene of unknown function, physiologically expressed in stratified epithelia, is associated with poor prognosis of several human malignancies. Here, we showed thatSBSNis expressed in the BM by myeloid cell subpopulations, including myeloid-derived suppressor cells, and is secreted into BM plasma and peripheral blood of MDS patients. The highest expression ofSBSNwas present in a patient group with poor prognosis.SBSNlevels in the BM correlated positively with blast percentage and negatively with CCL2 chemokine levels and lymphocyte count.In vitrotreatment of leukemic cells with interferon-gamma and demethylating agent 5-azacytidine (5-AC) inducedSBSNexpression. This indicated that aberrant cytokine levels in the BM and epigenetic landscape modifications in MDS patients may underlie ectopic expression ofSBSN. Our findings suggest SBSN as a candidate biomarker of high-risk MDS with a possible role in disease progression and therapy resistance.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Molecular Oncology
ISSN
1574-7891
e-ISSN
—
Volume of the periodical
14
Issue of the periodical within the volume
10
Country of publishing house
US - UNITED STATES
Number of pages
17
Pages from-to
2403-2419
UT code for WoS article
000557864300001
EID of the result in the Scopus database
—